{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T09:00:45Z","timestamp":1791450045242,"version":"4.3.3"},"reference-count":17,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T00:00:00Z","timestamp":1595376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Taiho Oncology, Inc."},{"name":"Taiho Pharmaceutical Co., Ltd."}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.annonc.2020.06.018","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T11:58:48Z","timestamp":1593691128000},"page":"1405-1412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":155,"title":["Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1\u20134 inhibitor in patients with advanced solid tumors"],"prefix":"10.1016","volume":"31","author":[{"given":"R.","family":"Bahleda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Meric-Bernstam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Yamamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.A.","family":"Benhadji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Matos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-T.","family":"Arkenau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2020.06.018_bib1","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1158\/1541-7786.MCR-10-0168","article-title":"Roles of fibroblast growth factor receptors in carcinogenesis","volume":"8","author":"Haugsten","year":"2010","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.annonc.2020.06.018_bib2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.06.018_bib3","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2020.06.018_bib4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2020.06.018_bib5","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated locally advanced or metastatic cholangiocarcinoma: a multicentre open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2020.06.018_bib6","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.annonc.2020.06.018_bib7","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-18-1959","article-title":"A\u00a0phase I, open-label, multicenter, dose-escalation study of the oral selective FGFR inhibitor Debio 1347 in patients with advanced solid tumors harboring FGFR gene alterations","volume":"25","author":"Voss","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.annonc.2020.06.018_bib8","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/onc.2012.319","article-title":"Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance","volume":"32","author":"Chell","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.annonc.2020.06.018_bib9","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1593\/neo.121106","article-title":"The N550K\/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors","volume":"15","author":"Byron","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.annonc.2020.06.018_bib10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2020.06.018_bib11","doi-asserted-by":"crossref","first-page":"A270","DOI":"10.1158\/1535-7163.TARG-13-A270","article-title":"Abstract A270: TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities","volume":"12","author":"Ochiiwa","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2020.06.018_bib12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/cmdc.201800719","article-title":"TAS-120 cancer target binding: defining reactivity and revealing the first fibroblast growth factor receptor 1 (FGFR1) irreversible structure","volume":"14","author":"Kalyukina","year":"2019","journal-title":"ChemMedChem"},{"key":"10.1016\/j.annonc.2020.06.018_bib13","doi-asserted-by":"crossref","first-page":"A271","DOI":"10.1158\/1535-7163.TARG-13-A271","article-title":"Abstract A271: TAS-120, an irreversible FGFR inhibitor, was effective in tumors harboring FGFR mutations, refractory or resistant to ATP competitive inhibitors","volume":"12","author":"Sootome","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2020.06.018_bib14","doi-asserted-by":"crossref","first-page":"526","DOI":"10.2174\/138920010791636185","article-title":"Systematic evaluation of dose proportionality studies in clinical pharmacokinetics","volume":"11","author":"Sheng","year":"2010","journal-title":"Curr Drug Metab"},{"key":"10.1016\/j.annonc.2020.06.018_bib15","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1002\/jbmr.478","article-title":"FGF receptors control vitamin D and phosphate homeostasis by mediating renal FGF-23 signaling and regulating FGF-23 expression in bone","volume":"26","author":"Bonny","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.annonc.2020.06.018_bib16","doi-asserted-by":"crossref","first-page":"A272","DOI":"10.1158\/1535-7163.TARG-13-A272","article-title":"Abstract A272: intermittent treatment with TAS-120, an irreversible FGFR inhibitor, is effective in tumors harboring a FGFR gene abnormality","volume":"12","author":"Nakatsuru","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.annonc.2020.06.018_bib17","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420399282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753420399282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T05:59:40Z","timestamp":1760335180000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753420399282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0923753420399282"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2020.06.018","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1\u20134 inhibitor in patients with advanced solid tumors","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2020.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}